Loading
WD-930 is an experimental small molecule from Zhejiang Wenda Pharma, in preclinical development for advanced cancer; its current status is not stated.
WD-930 is a small molecule from Zhejiang Wenda Pharma. Described only as a brain-penetrant, highly selective inhibitor with a 'trapping' function, being explored for cancer. The target is not named. Its furthest stage is preclinical development, for advanced cancer (unspecified). No clinical trial naming it is registered on ClinicalTrials.gov. No stage given on the pipeline page and no registered trial found; listed for 'Advanced cancer'. It has not been shown to work in people.
Described only as a brain-penetrant, highly selective inhibitor with a 'trapping' function, being explored for cancer. The target is not named.
1.WD-930 slips into a pocket on its target.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"WD-930" OR ABSTRACT:"WD-930") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about WD-930, not a curated reading list.
Shares Zhejiang Wenda Pharma, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Zhejiang Wenda Pharma, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Zhejiang Wenda Pharma and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/